ArticleTheranostics2026
A dual CEST-fluorescent reporter enables cross-validated tracking of hematopoietic engraftment in deep bone marrow.
Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reporter gene imaging can enable detection of engineered cells Methods: A lentiviral dual-reporter cassette co-expressing the red fluorescent protein mScarlet-I (mScarlet) and the CEST-MRI reporter SuperCESTide (SC) via a T2A linker was evaluated in CT26 colon carcinoma cells Results: The dual mScarlet-SuperCESTide reporter showed efficient expression in CT26 cells and generated detectable red fluorescence and increased CEST-MRI contrast in reporter-positive tumors compared with contralateral non-transduced controls. Conclusion: We developed a dual CEST-fluorescent reporter platform that enables cross-validated imaging of reporter-transduced hematopoietic cells in deep BM. By integrating noninvasive CEST-MRI with fluorescence-based cellular validation, this feasibility study establishes a preclinical framework for cross-validated, noninvasive assessment of engineered hematopoietic cell localization and persistence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.